
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc. has shown significant advancements in its clinical-stage assets, particularly with ALTO-207 (CTC-501), which has demonstrated improved tolerability compared to pramipexole, allowing for higher doses and fast titration that enhance treatment benefits for depressive symptoms. In FY24, the company generated $1.08 billion in revenue, marking an approximate 60% increase from FY23 and indicating strong market demand and growing confidence in its innovative therapies. Additionally, the development of a new transdermal formulation for ALTO-101, which has shown an improved safety profile and favorable pharmacokinetics, further supports the potential for successful outcomes in ongoing clinical trials.
Bears say
Alto Neuroscience Inc has encountered significant challenges, particularly following the failure of its lead asset, ALTO-100, in a pivotal Phase 2b study for major depressive disorder (MDD), which has negatively impacted investor confidence. The company's ongoing clinical programs, including a Phase 2b study in bipolar depression, carry inherent risks and have previously yielded disappointing results, suggesting a low probability of success (POS). Additionally, emerging evidence indicates that deficits in neuroplasticity among patients, including those with cognitive disorders, may exacerbate treatment resistance and hinder therapeutic outcomes, further compounding the company's challenges in developing effective psychiatric treatments.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares